All treatments
Treatment
Neladalkib (NVL-655) clinical trials
2 indexed studies · 2 currently recruiting
- RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
For: Non-small Cell Lung Cancer · Anaplastic Lymphoma Kinase-positiveUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
This study is testing a new drug, neladalkib, for advanced cancers that have a specific genetic change called ALK rearrangement. It's looking at how safe the drug is and if it shrinks tumours in people with certain types of lung cancer and other solid tumours.
For: Locally Advanced Solid Tumor · Metastatic Solid TumorUnited States · Australia · Belgium